Document is current
Any future updates will be listed below
-
Authors
Pan, Xiaoguang
Qu, Kunli
Yuan, Hao
Xiang, Xi
Anthon, Christian https://orcid.org/0000-0002-4336-1688
Pashkova, Liubov https://orcid.org/0000-0002-7195-9329
Liang, Xue
Han, Peng https://orcid.org/0000-0002-3405-087X
Corsi, Giulia I. https://orcid.org/0000-0001-5932-0664
Xu, Fengping
Liu, Ping
Zhong, Jiayan
Zhou, Yan
Ma, Tao
Jiang, Hui
Liu, Junnian
Wang, Jian
Jessen, Niels https://orcid.org/0000-0001-5613-7274
Bolund, Lars
Yang, Huanming
Xu, Xun https://orcid.org/0000-0002-5338-5173
Church, George M.
Gorodkin, Jan https://orcid.org/0000-0001-5823-4000
Lin, Lin https://orcid.org/0000-0002-7546-4948
Luo, Yonglun https://orcid.org/0000-0002-0007-7759
- License Information
-
More Information
Article History
Received: 7 March 2022
Accepted: 20 June 2022
First Online: 13 July 2022
Competing interests
: G.M.C.’s advisory roles and funding sources are listed at v.ht/PHNc. He holds equity in Editas, Caribou Biosciences, Intellia and EGenesis, which might benefit from perceived progress in targeting CRISPR. The remaining authors declare no competing interests.
